about
Genetic Association of Peptidoglycan Recognition Protein Variants with Inflammatory Bowel DiseaseWhen should potentially false research findings be considered acceptable?Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology GroupEstimating the mean and variance from the median, range, and the size of a sampleUse of re-randomized data in meta-analysis.Intravesical therapy for non-muscle invasive bladder cancer: a network meta-analysisPeptidoglycan recognition proteins kill bacteria by inducing oxidative, thiol, and metal stressOptimism bias leads to inconclusive results-an empirical study.Uncertainty about effects is a key factor influencing institutional review boards' approval of clinical studies.Decision-making when data and inferences are not conclusive: risk-benefit and acceptable regret approach.Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer.A regret theory approach to decision curve analysis: a novel method for eliciting decision makers' preferences and decision-making.How do physicians decide to treat: an empirical evaluation of the threshold model.A social network analysis of treatment discoveries in cancer.Instrumental variable meta-analysis of individual patient data: application to adjust for treatment non-compliance.Effect of initial conditions on reproducibility of scientific research.Extensions to regret-based decision curve analysis: an application to hospice referral for terminal patients.When is it rational to participate in a clinical trial? A game theory approach incorporating trust, regret and guiltDual processing model of medical decision-making.Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials.When is diagnostic testing inappropriate or irrational? Acceptable regret approach.Evaluation of new treatments in radiation oncology: are they better than standard treatments?Dual Processing Model for Medical Decision-Making: An Extension to Diagnostic Testing.Monte Carlo decision curve analysis using aggregate data.Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006.Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review.Trial sequential analysis may be insufficient to draw firm conclusions regarding statistically significant treatment differences using observed intervention effects: a case study of meta-analyses of multiple myeloma trials.When is rational to order a diagnostic test, or prescribe treatment: the threshold model as an explanation of practice variation.Acceptable regret model in the end-of-life setting: Patients require high level of certainty before forgoing management recommendations.Rationality, practice variation and person-centred health policy: a threshold hypothesis.Optimal type I and type II error pairs when the available sample size is fixed.Determining optimal threshold for statins prescribing: individualization of statins treatment for primary prevention of cardiovascular disease.Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis.The predicament of patients with suspected Ebola.Study design and the drug development process--reply.Optimal information size in trial sequential analysis of time-to-event outcomes reveals potentially inconclusive results because of the risk of random error.Expected utility versus expected regret theory versions of decision curve analysis do generate different results when treatment effects are taken into account.Eliciting regret improves decision making at the end of life.When to perform hepatic resection for intermediate-stage hepatocellular carcinoma.Improving the drug development process: more not less randomized trials.
P50
Q21133003-010E79A2-8BC0-42FA-9F45-861FA17D3E54Q24288771-CD8A97BE-234E-46EF-9240-5BB6F7CA285AQ24536914-B8253C5B-357B-42B3-AE51-371289198E58Q24801782-D36AAC19-5520-42B7-BAC3-6CDB547DC6E5Q24810349-A66633E1-41B0-4ACE-9E8A-969824A5BD4AQ26471299-E77268C0-2505-4A44-9308-3752C6195AEBQ28540887-958A5D6D-0454-4B4F-BB0F-B17148B74A2BQ30426685-1C624D18-4EF7-43E3-90B6-10CFC74ADBD5Q30458853-340B2DA0-D53F-4DFE-B945-77A378B47F22Q31160587-5CDC3A22-EF69-4D4F-8DEB-B6B2A7E94AACQ33508848-B235156A-0F66-49AE-B951-B5E89CED1F40Q33693923-588E9A5C-2296-4691-99FE-5B7182A175BAQ33747436-5C774716-1CC3-4222-862D-41AE70FB91EEQ33862463-299200DD-24D2-45FC-AB5A-2996D3ECBE50Q33879113-83B2A8AB-DE72-4F13-BD7B-075FF1880A79Q34035893-04AC9A34-3783-4A9A-B8B2-6721840AEC7BQ34111407-3CDF2C51-D362-4824-977B-9DFE2FBDF13FQ34314845-E4B90128-EC48-4DA9-8581-64C95F4F6E29Q34401953-EF66791A-EE13-47C7-8278-E06225B20B91Q34650505-7C28FA1B-B199-4A57-93E2-B4C09D23DA45Q34778608-46C6CE6D-776D-4E96-B73D-E8D57A5124BBQ35606349-9644036A-8879-47B6-AB76-9FFDAE57DC23Q35921388-EB3421A9-F9D7-480B-B4D9-8E603F742B49Q36237352-EAB3D559-A38A-435F-98D0-97F89779BCBEQ37412411-8D1CBA20-00FD-465A-B4EE-4C6EBD8D90CBQ37814273-D3E681BB-751A-4243-AC26-D5A0D156D1BEQ38070310-7A4373AC-567F-492F-9100-650F7F1FE043Q38353140-55AC61F8-0A81-41A4-8258-5F2987BEBB82Q38943247-D8D3082F-8A0F-4984-82DC-1C10AB0259F2Q38974508-EE39A5CC-D24D-4EAE-8A03-419D01044504Q39420873-85B5B314-B140-49D4-8C3C-458125DD8BF2Q40337089-DD3F9E57-7E5C-4B14-B35A-4DAD126321F8Q42922537-AFCAFC38-A912-4988-8264-0118CC6B7AC1Q44105125-38BA6935-767B-4124-9733-6645E1251BF9Q46170393-89981FEE-1344-478A-9D1D-12D7CC054D1FQ47254961-48DFB05E-B121-46A3-BD17-C2ABF0F56EFAQ47362526-0CD86EDA-60B4-4CA9-88D3-6A0C92FFE747Q47387003-A6B7E89A-655D-444C-8B6A-7F94712FB383Q47843414-BC28677C-59FF-43F6-97CF-30E7FA2CD65EQ48092634-2B508F7C-5FF3-4AB2-AD90-F0EE0C56F986
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Iztok Hozo
@ast
Iztok Hozo
@en
Iztok Hozo
@es
Iztok Hozo
@nl
type
label
Iztok Hozo
@ast
Iztok Hozo
@en
Iztok Hozo
@es
Iztok Hozo
@nl
altLabel
Hozo I
@en
Hozo I.
@en
Hozo
@en
I Hozo
@en
I. Hozo
@en
prefLabel
Iztok Hozo
@ast
Iztok Hozo
@en
Iztok Hozo
@es
Iztok Hozo
@nl
P106
P31
P496
0000-0003-2349-5707